Q-omics provides the consensus-scored FNDC11 profile across patient tissues and cancer cell-line models. FNDC11 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FNDC11 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, FNDC11 RNA expression shows 17,075 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, COAD, and ACC as cancer lineages where FNDC11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FNDC11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FNDC11 survival associations across molecular data types. FNDC11 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FNDC11 RNA expression–survival associations across cancer types. High FNDC11 expression shows unfavorable associations in MESO, ACC, KIRC, LGG and TGCT, but favorable associations in COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FNDC11 RNA expression.
This table summarizes FNDC11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FNDC11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FNDC11 shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, HNSC, STAD and READ. The COAD box plot shows higher FNDC11 RNA expression in tumor versus normal tissue (log2 FC = +0.897, t-test p < 0.001).
This table shows molecular features associated with FNDC11 in patient tissues and cancer cell lines. In patient samples, FNDC11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FNDC11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
